Damian Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Damian Pharma is a clinical-stage biotech targeting a high-unmet need in endocrinology with a first-in-class therapy for Primary Aldosteronism (PA). The company's lead asset, dexfadrostat phosphate (DP13), has completed Phase I and a Phase II study, positioning it as a potential targeted medical alternative to surgery. Backed by a small team of seasoned pharmaceutical executives and scientists, Damian is leveraging a clear biological pathway to develop a precision medicine solution for a rare but serious endocrine disorder.

OncologyEndocrinology

Technology Platform

Targeted theranostic approach combining a novel aldosterone synthase inhibitor (dexfadrostat phosphate, DP13) with a companion PET diagnostic tracer (DP14) for aldosterone-producing adenomas.

Opportunities

Damian addresses a large, underdiagnosed market in Primary Aldosteronism, a leading cause of resistant hypertension with no targeted therapy.

Success with its first-in-class drug could establish a new standard of care and create a platform for expansion into other aldosterone-dependent conditions like heart failure and chronic kidney disease.

Risk Factors

Key risks include clinical failure in later-stage trials, the significant challenge of driving market adoption for an underdiagnosed disease, dependence on future fundraising as a private company, and potential competition from entrenched generic therapies or new market entrants.

Competitive Landscape

Direct competition is limited as there are no approved aldosterone synthase inhibitors. The main competitors are generic mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone) and adrenalectomy surgery. Larger pharma companies may have early-stage assets in this pathway, but Damian appears to be a clinical leader.

More companies in Switzerland →